✦ LIBER ✦

Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy

✍ Scribed by JUNG WOO SHIN; YOUNG-HWA CHUNG; MIN HEE CHOI; JEONG A KIM; SOO HYUNG RYU; MYOUNG KUK JANG; IN SOOK KIM; NEUNG HWA PARK; HAN CHU LEE; YUNG SANG LEE; DONG JIN SUH

Book ID: 108950282
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 83 KB
Volume: 20
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.2005.03824.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Association of core promoter mutations w

Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy

✍ Syed Naqui Kazim; Ranjit Chauhan; Bhudev Chandra Das; Shiv Kumar Sarin 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB

Lamivudine therapy in patients undergoin

Lamivudine therapy in patients undergoing liver transplantation for hepatitis b virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immu

✍ McCaughan, Geoffrey W. ;Spencer, Jenean ;Koorey, David ;Bowden, Scott ;Bartholom 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 75 KB 👁 1 views

Recurrent hepatitis B virus (HBV) infection remains a major cause of morbidity and mortality after liver transplantation. Recently, antiviral therapy, such as lamivudine, has become available for prophylaxis against HBV reactivation posttransplantation and for the treatment of HBV recurrent disease.